Navigation Links
On track with the FDA -- But what about your coverage and reimbursement strategy?

Food and Drug Administration (FDA) approval or authorization is critical to any new medical technology or treatment's success. But coverage and reimbursement issues can be just as determinative.

"Coverage" is whether there will be payment by an insurer for the product. "Reimbursement" is how much payment there will be if there is coverage.

Unlike ......

Full article >>> edicare has enormous influence over other health plans because once Medicare agrees to pay for a new treatment, other insurers often follow suit.

Roles of the FDA and CMS

Medicare includes several major programs with different rules and administrative systems. All are managed by the Centers for Medicare and Medicaid (CMS). CMS, like the FDA, is an agency within the U.S. D......

Full article >>> uctures pay too low.

In making coverage decisions, CMS considers the following issues:

Does the product have FDA marketing approval or authorization (required except for certain investigational medical devices)?

Is it appropriate for the Medicare population?

Has it been proven medically necessary for the relevant disease or condition?

Does it improv......

Full article >>> ent decisions, such as studies that have both clinical and pharmacoeconomic endpoints (i.e., comparisons to existing technologies or treatments)

Early planning is essential to help ensure that the product will be covered and reimbursed appropriately.

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/11/2017)... ... ... Back pain relief technology is now available without a prescription at What ... relief for WAR members. , This spinal restoration platform boasts utilization of technology that ... suffering from chronic back pain. , What A Relief Back Pain Centers ...
(Date:1/11/2017)... , PITTSBURGH and BENGALURU, ... (NASDAQ, TASE: MYL) and Biocon Ltd. (BSE code: 532523, ... Drug Administration (FDA) has accepted Mylan,s biologics license application ... through the 351(k) pathway. This product is a proposed ... certain HER2-positive breast cancers. The anticipated FDA goal date ...
(Date:1/11/2017)... , Jan. 11, 2017  GenVec, Inc. ... delivery company, announced today that its chief scientific ... a talk entitled  "AdenoVerse™ platform for translational development ... Biotech Showcase at the upcoming Phacilitate Cell & ... Miami , Florida.  Dr. Brough,s presentation will ...
(Date:1/11/2017)... (PRWEB) , ... January 11, 2017 , ... ... signed a multi-year license agreement with Poseida Therapeutics Inc, the San Diego based ... genetic data. Poseida Therapeutics selected KBioBox in order to harness KBioBox’s powerful BioEngine ...
Breaking Biology Technology:
(Date:1/12/2017)...  Trovagene, Inc. (NASDAQ: TROV ), a ... that it has signed agreements with seven strategic partners ... Middle East for commercialization of the ... wave of international distribution agreements for Trovagene,s CLIA based ... The initial partners will introduce Trovagene,s liquid biopsy ...
(Date:1/11/2017)... -- Michael Johnson, co-founder of Visikol Inc. a company originally funded with ... to the elite "Forbes 30 Under 30" list in the Science ... 20 fields nationwide to be recognized as a leader in business ... ... a PhD candidate at Rutgers University. Visikol ...
(Date:1/4/2017)... thousands of attendees at this year,s International Consumer Electronics Show (CES), ... devices and services, will be featuring its new line of ULTRA CONNECT ... special CES Exhibit Suite , the new upper arm and wrist smart ... product platform.  Continue Reading ... ...
Breaking Biology News(10 mins):